Reversing Humanity’s #1 Killer - Arterial Plaque | Dr. Matthew O’Connor - Cyclarity Therapeutics

Key Takeaways

• Phase 1 trial of UDP‑0003 showed safe, dose‑dependent urinary 7KC excretion.
• Dimeric cyclodextrin binds 7KC 1,000× stronger than monomeric forms.
• 7KC accumulation drives foam‑cell formation and plaque instability.
• Removing 7KC may enable reversal of existing atherosclerotic plaque.
• Cyclarity plans Phase 2 imaging trials to assess plaque volume reduction.

Pulse Analysis

Cardiovascular disease remains the leading cause of death worldwide, and existing therapies such as statins, PCSK9 inhibitors, and RNA‑based drugs primarily lower circulating LDL cholesterol or blunt systemic inflammation. While these interventions reduce the risk of new lesion formation, they do little to clear the entrenched, lipid‑laden plaques that already compromise arterial walls. This therapeutic gap has spurred interest in strategies that can directly dismantle plaque components, a shift that could transform the management of atherosclerosis from risk mitigation to true disease reversal.

One of the most toxic constituents of atherosclerotic plaque is 7‑ketocholesterol (7KC), an oxidized cholesterol species that accumulates when free radicals modify native cholesterol. Unlike ordinary cholesterol, 7KC cannot be processed by macrophage reverse‑cholesterol‑transport pathways, leading to lysosomal dysfunction, foam‑cell formation and plaque instability. Cyclarity’s solution is a dimeric cyclodextrin, UDP‑0003, engineered to act like a molecular “Pac‑Man” that selectively captures 7KC while sparing essential cholesterol. Computational carbohydrate modeling gave the dimer a thousand‑fold affinity boost over monomeric cyclodextrins, enabling efficient tissue extraction.

The Phase 1 trial of UDP‑0003 in 72 participants showed a clean safety profile, a short three‑hour half‑life and a clear dose‑responsive rise in urinary 7KC, confirming that the oxysterol can be mobilized and eliminated via the kidneys. If Phase 2 imaging studies demonstrate reductions in plaque volume, the technology could open a new class of “plaque‑clearing” drugs and attract substantial investment from both biotech and pharmaceutical sectors. Moreover, because 7KC is implicated in neurodegeneration and other age‑related conditions, the platform may have far‑reaching therapeutic relevance.